<code id='1A13FC37C8'></code><style id='1A13FC37C8'></style>
    • <acronym id='1A13FC37C8'></acronym>
      <center id='1A13FC37C8'><center id='1A13FC37C8'><tfoot id='1A13FC37C8'></tfoot></center><abbr id='1A13FC37C8'><dir id='1A13FC37C8'><tfoot id='1A13FC37C8'></tfoot><noframes id='1A13FC37C8'>

    • <optgroup id='1A13FC37C8'><strike id='1A13FC37C8'><sup id='1A13FC37C8'></sup></strike><code id='1A13FC37C8'></code></optgroup>
        1. <b id='1A13FC37C8'><label id='1A13FC37C8'><select id='1A13FC37C8'><dt id='1A13FC37C8'><span id='1A13FC37C8'></span></dt></select></label></b><u id='1A13FC37C8'></u>
          <i id='1A13FC37C8'><strike id='1A13FC37C8'><tt id='1A13FC37C8'><pre id='1A13FC37C8'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:1394
          The FDA building -- First Opinion coverage from STAT
          Adobe

          The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

          The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

          advertisement

          Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          FDA's naming rule on biosimilars has undermined competition
          FDA's naming rule on biosimilars has undermined competition

          AdobeIrecentlytriedtoorderwhitebloodcellgrowthfactor(pegfilgrastim)biosimilarforoneofmypatients.This

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          FDA poised to publish guidelines for clinical trial diversity

          AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc